Recent

% | $
Quotes you view appear here for quick access.

Alcatel-Lucent Message Board

tickerguy_2000 47 posts  |  Last Activity: 13 hours ago Member since: Apr 6, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tickerguy_2000 by tickerguy_2000 13 hours ago Flag

    Good news travels fast. Bad news travels slowly or not at all. Neuralstem filed for a phase II NSI-189 trial in September of 2015, so far investors have heard nothing in regard to the approval. The FDA commonly takes six months or so to approve such requests. Considering that the FDA approval for a 1b trial only took two months from the completion of Neuralstem's NSI-189 1a trial, one would think word in regard to a yea or nay from the FDA would have been received by now. Has the FDA not approved the phase II trial for NSI-189 and investors are not being told or told that the approval is pending ----- a pending situation that could go on for years or an indefinite period of time?

    If all was perfect with the application, would not the good news of a FDA approval been received by now and if all was not good, then an indefinite delay in the approval with investors hearing only the sound of silence. Of course, in the investment world it is always good to anticipate good news for a company "Ahead Of The Crowd". ..............Tickerguy

  • The management of this company has made extremely poor business decisions over the past year. As a result of those decisions, the shares have declined 75% over the past 52 weeks . (The stock is now 32cents a share down from its high of $1.39.)

    What should shareholders do about this?

    1. Well, for starters, give McGlynn more than one million dollars to abandon the ship. (DONE!!)
    2. Second, fire a lot of people that have worked very hard to make management's poor decisions to work out.
    3. Third, award 6,253,751 shares to officers and directors from January 2, 2016 through January 29th, 2016
    4. Last but not least, prepare for delisting and bankruptcy.

    Welcome to Stem Cell Inc.

  • Reply to

    Something To Ask Neuralstem Management about

    by tickerguy_2000 Dec 12, 2015 8:18 AM
    tickerguy_2000 tickerguy_2000 Feb 8, 2016 1:00 PM Flag

    semi,

    I would say but the reason I made my original post was to motivate all posters on this message board to, shall I say, harass management about the delay. Also, by each poster calling, each can judge for themselves whether or not the delay was justified.

  • Reply to

    Something To Ask Neuralstem Management about

    by tickerguy_2000 Dec 12, 2015 8:18 AM
    tickerguy_2000 tickerguy_2000 Feb 8, 2016 6:53 AM Flag

    I did

  • The NSI-189/MDD Phase Ia and Ib trials were randomized, double-blind, placebo-controlled, multiple-dose escalating trials evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189.

    1. February 2011-----Phase Ia initiated (single dose to healthy volunteers)
    2. October 2011----- Phase Ia completed
    3. December 2011---Phase Ib, approved by the FDA (safety of escalating doses)
    4. June 2012----------Phase Ib, commenced (28 daily doses to 24 depressed patients)
    5. April 2013---------Phase Ib,FDA approved dosing of the third cohort
    6. November 2013---Phase Ib trial completed
    7. June 2014----------Phase Ib data reported at ASCP and CINP

    Phase Ib data presented at the ASCP Annual Meeting by Marlene Freeman, MD, Medical Director, Clinical Trials Network and Institute, Massachusetts General Hospital, and Associate Professor of Psychiatry, Harvard Medical School, showed a clinically meaningful reduction in cognitive and depressive symptoms across all measures in depressed patients on NSI-189 active therapy against the control group, continuing for the duration of the trial, eight weeks after the 28-day treatment had stopped. Data further showed that results continued for eight weeks post-trial, despite the fact that there was no accumulation of the drug in the patients’ systems. A large effect was reported in all four scales employed in the study that are commonly used to assess clinical levels of depression and improvement: Montgomery-Asberg Depression Rating Scale (MADRS), Clinician Global Impression–Improvement (CGI-I), Symptoms of Depression Questionnaire (SDQ), and Cognitive and Physical Functioning Questionnaire (CPFQ). Based on the results, the investigators concluded NSI-189 is a promising new treatment for MDD.
    However the above timetable indicates investors have about a two year wait before NSI-189 will be commerciall

  • tickerguy_2000 by tickerguy_2000 Feb 4, 2016 12:23 PM Flag

    The management of this company has made extremely poor business decisions over the past year. As a result of those decisions, the shares have declined 75% over the past 52 weeks . (The stock is now 35cents a share down from its high of $1.39.)

    What should shareholders do about this?
    1. Well, for starters, give McGlynn more than one million dollars to abandon the ship.
    2. Second, fire a lot of people that have worked very hard to make management's poor decisions to work out.
    3. Third, award 6,253,751 shares to officers and directors from January 2, 2016 through January 29th, 2016
    4. Last but not least, prepare for delisting and bankruptcy.

    Welcome to Stem Cell Inc.

  • tickerguy_2000 by tickerguy_2000 Feb 4, 2016 5:34 AM Flag

    STEM has admitted failure by IMMEDIATELY discontinuing its AMD trial. A company does not discontinue a trial because it is a success.

  • real money stem cell can ill afford to throw away, however, throw it away they did. ONE MILLION DOLLARS TO FIRE STEM CELLS CEO! Come on man, just fire him for incompetence don't throw a million dollars at him just to get him to leave. Oh well what is done is done and now Stem Cell inc will run out of money just that much sooner as it glides into delisting and bankruptcy. Stemoron you should be proud of yourself!!!

  • dogface why was Neuralstem up AGAIN today (up over 14% today) and up over 16% last Friday! Answer that!

    I do get so sick of your nattering naybob attitude! So what is your negative spin on why Neuralstem was up today and Friday? Come on man! You have been ducking this question for days! Why can't you answer such a simple question?

  • Reply to

    So why is this bad?

    by pmkhoopster Feb 1, 2016 8:13 AM
    tickerguy_2000 tickerguy_2000 Feb 1, 2016 8:43 AM Flag

    ALU does not make phones, they sold that division some time ago. The selling agreement allowed the buyer to continue to use the "Alcatel" name on the phone but it is not ALU that makes the phone or profits from the sale of the phone.

    Many investor still think Alcatel-Lucent still makes phones but they do not.

  • Reply to

    dogface why was Neuralstem up over 16% today?

    by tickerguy_2000 Jan 29, 2016 11:52 PM
    tickerguy_2000 tickerguy_2000 Feb 1, 2016 4:57 AM Flag

    Come on dogface answer the question!

  • dogface why was Neuralstem up today and up over 16%? Answer that! I do get so sick of your nattering naybob attitude! So what is your negative spin on why the stock was up today?

    Come on man, answer the question!

  • tickerguy_2000 tickerguy_2000 Jan 29, 2016 6:14 PM Flag

    My guess is Nokia asked for the delay so they could announce it at the same time as their earnings report. Just kidding. Hope and patience are great gifts, thank you arbitration people! Not kidding.

  • tickerguy_2000 tickerguy_2000 Jan 29, 2016 5:56 PM Flag

    you_are_mentally_sick,

    When you want to say "there is" the contraction for is not "theres". Many people will judge your posts by your grammar. Do you know what I am saying?

    Speaking of judging, you seem to make quite a few judgements about Neuralstem Inc., so what is your explanation about why Neuralstem went UP over 16% today? Why up over 16%? Why? you_are_mentally_sick, WHY!?

    Did you know your eyes never grow but your ears and nose never stop growing?
    Did you know strawberries are not berries but bananas are?
    Did you know Neuralstem was up over 16% today?

    Looking forward to your answers "Ahead Of The Crowd". .............Tickerguy

  • Reply to

    Where there's will, thee's a way

    by robegratz Jan 22, 2016 6:14 PM
    tickerguy_2000 tickerguy_2000 Jan 24, 2016 11:04 AM Flag

    Freddie Mercury's headstone reads: "A singer of songs, A lover of life". Guess the same can be said for Freddie the cow----except for the singing part. Long live Freddie!

  • tickerguy_2000 by tickerguy_2000 Jan 22, 2016 6:58 AM Flag

    For the stock as a whole, how much lower do you think we go? This is not in regards to the Dow Jones.
    I'm going to say the low has been reached if the company survives.

  • tickerguy_2000 by tickerguy_2000 Jan 19, 2016 9:51 AM Flag

    The investing crowd values Nokia at $7.14 dollars per share, however:
    1. Argus research has a $12 per share price target for NOK and
    2.Credit Suisse raised Nokia to Outperform from Neutral on December 1, 2015.
    3.BMO Capital Markets raised Nokia to Outperform from Market Perform on November 4, 2015.
    4.CLSA started Nokia as Buy on September 22, 2015.
    5.Deutsche Bank raised Nokia to Buy from Hold on September 21, 2015.
    6.Goldman Sachs already had a Buy rating but added Nokia to its prized Conviction Buy list on September 14, 2015.

    So, now you know where Nokia share price is headed "Ahead Of The Crowd". ............Tickerguy

  • tickerguy_2000 by tickerguy_2000 Jan 18, 2016 5:53 AM Flag

    Argus research has a $12 per share price target for NOK and
    Credit Suisse raised Nokia to Outperform from Neutral on December 1, 2015.
    BMO Capital Markets raised Nokia to Outperform from Market Perform on November 4, 2015.
    CLSA started Nokia as Buy on September 22, 2015.
    Deutsche Bank raised Nokia to Buy from Hold on September 21, 2015.
    Goldman Sachs already had a Buy rating but added Nokia to its prized Conviction Buy list on September 14, 2015.

    So, now you know "Ahead Of The Crowd". ............Tickerguy

  • "To gain control of the remaining shares that weren't tendered, Nokia is reopening the offering, and if it achieves 95% ownership, plans to "squeeze out" the remaining shareholders. And after the merger, as part of Nokia's 7 billion euro capital structure optimization program, it intends to return some 4 billion euros to its shareholders. Alcatel Lucent shareholders, however, will be precluded from receiving any of the windfall."

    Does the above mean instead of tendering Alcatel-Lucent shareholders should have sold their ALU shares and bought 55 shares of NOK for every hundred shares of ALU sold to be entitled to the dividend?

  • pkbaker,

    You have no idea what you are talking about. You are just babbling and babbling. Yes, OH YES! You are a BITTER BABBLER!

    I know soon you will be gone, so babble on! Those that are smart will put you on IGNORE "Ahead Of The Crowd". ............Tickerguy

ALU
3.3633+0.0533(+1.61%)11:23 AMEST